William J. Sandborn - Apr 28, 2023 Form 4 Insider Report for Ventyx Biosciences, Inc. (VTYX)

Role
President and Chief Medical Officer
Signature
/s/ Christopher Krueger, as Attorney-in-Fact
Stock symbol
VTYX
Transactions as of
Apr 28, 2023
Transactions value $
-$396,597
Form type
4
Date filed
5/1/2023, 05:36 PM
Previous filing
Jan 18, 2023
Next filing
May 16, 2023

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction VTYX Common Stock Options Exercise $2.16K +10.8K +22.3% $0.20* 59.2K Apr 28, 2023 Direct
transaction VTYX Common Stock Sale -$141K -3.89K -6.57% $36.17 55.3K Apr 28, 2023 Direct F1, F2
transaction VTYX Common Stock Sale -$258K -6.9K -12.49% $37.40 48.4K Apr 28, 2023 Direct F1, F3
holding VTYX Common Stock 34.9K Apr 28, 2023 By Spouse

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction VTYX Stock Option (Right to Buy) Options Exercise $0 -10.8K -33.5% $0.00 21.4K Apr 28, 2023 Common Stock 10.8K $0.20 Direct F4
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on December 19, 2022.
F2 Represents the weighted average share price of an aggregate total of 3,886 shares sold in the price range of $35.8292 to $36.6489. The reporting owner undertakes to provide upon request by the Commission staff, the issuer or a security holder of the issuer, full information regarding the number of shares sold at each separate price.
F3 Represents the weighted average share price of an aggregate total of 6,904 shares sold in the price range of $36.895 to $37.61. The reporting owner undertakes to provide upon request by the Commission staff, the issuer or a security holder of the issuer, full information regarding the number of shares sold at each separate price.
F4 Subject to the Reporting Person continuing to be a Service Provider (as defined in the Issuer's 2019 Equity Incentive Plan) through each applicable date, one thirty-sixth (1/36th) of the total shares subject to the option shall vest each month following the Vesting Commencement Date on the same day of the month as the Vesting Commencement Date (and if there is no corresponding day, on the last day of the month). "Vesting Commencement Date" shall mean February 6, 2019.

Remarks:

President and Chief Medical Officer